Hypothesis

Morning bright light exposure (>3000 lux or blue‑enriched) within the first hour after waking amplifies the cortisol awakening response (CAR), which in turn upregulates astrocytic aquaporin‑4 (AQP4) polarity and enhances glymphatic clearance during the subsequent night’s slow‑wave sleep (SWS), leading to a measurable increase in N3 percentage and sleep efficiency.

Mechanistic Rationale

Morning light activates melanopsin‑containing ipRGCs, signaling the SCN to suppress melatonin and advance DLMO[1]. This same SCN‑driven signal stimulates the hypothalamic‑pituitary‑adrenal axis, producing a robust CAR[3]. Cortisol binds glucocorticoid receptors on astrocytes, triggering rapid translocation of AQP4 to perivascular endfeet, a prerequisite for efficient glymphatic flow[2]. Enhanced glymphatic clearance reduces interstitial accumulation of metabolic waste (e.g., adenosine, amyloid‑β), lowering homeostatic sleep pressure and allowing deeper, more stable SWS[4][5]. Individuals with higher melanopsin sensitivity exhibit larger CARs[9], predicting greater AQP4‑mediated clearance and thus larger gains in N3%; conversely, blunted CAR yields minimal SWS improvement despite identical light dosing.

Testable Predictions

1. Participants receiving a standardized morning light protocol (30 min ≥ 3000 lux blue‑enriched) will show a significantly larger CAR (area under the curve 0‑30 min post‑wake) compared with a dim‑light control (<10 lux).
2. The magnitude of the CAR will positively correlate with the percentage of N3 sleep recorded that night via polysomnography or validated wearable EEG (e.g., frontal dry electrodes), controlling for total sleep time and sleep efficiency.
3. Pharmacological attenuation of cortisol synthesis (e.g., single dose metyrapone) administered after the morning light session will abolish the CAR‑N3 relationship, returning N3% to baseline levels.
4. Blocking AQP4 polarization (using a selective AQP4 inhibitor such as TGN‑020) in a subset of participants will prevent the CAR‑driven increase in N3%, confirming glymphatic involvement.

Potential Outcomes and Falsifiability

• If CAR amplitude predicts N3% gains and manipulation of cortisol or AQP4 disrupts this link, the hypothesis is supported.
• If no correlation exists between CAR and N3%, or if cortisol/AQP4 inhibition fails to alter the light‑induced SWS enhancement, the hypothesis is falsified.
• Secondary outcomes (REM%, sleep efficiency, HRV) should remain unchanged, isolating the effect to SWS and preserving specificity.

This framework connects circadian photic input, neuroendocrine arousal, and glial water transport to explain individual variability in sleep architecture improvements from morning light, offering a concrete, falsifiable pathway for future investigation.